Clinical Research Directory
Browse clinical research sites, groups, and studies.
4 clinical studies listed.
Filters:
Tundra lists 4 Parkinson Disease Psychosis clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT05824728
Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams.
Gender: All
Ages: 40 Years - 85 Years
Updated: 2025-10-14
1 state
NCT05357612
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
Gender: All
Ages: 50 Years - 85 Years
Updated: 2025-08-12
1 state
NCT06793995
Effect of Food and Age on the Pharmacokinetics of LY03017
This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults. Part B is a single-arm study to evaluate the safety and pharmacokinetics of LY03017 in elderly volunteers.
Gender: All
Ages: 18 Years - Any
Updated: 2025-01-27
NCT05995782
A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects.
Gender: All
Ages: 19 Years - Any
Updated: 2024-12-02